PulseSight tees up first human PST-611 data in geographic atrophy

PulseSight Therapeutics said it has completed follow-up in its first-in-human Phase I PST-611-CT1 study and will present trial results for PST-611 in dry age-related macular degeneration with geographic atrophy at the ARVO 2026 meeting in Denver. The company said six patients were treated across two dose cohorts at two dose levels in Paris and Grenoble, with the study designed to assess safety and tolerability and help set a dose for a planned Phase IIa trial. PST-611 is a non-viral, plasmid-based gene therapy intended to express transferrin, with the goal of correcting iron dysregulation implicated in retinal damage in geographic atrophy. (globenewswire.com)

Why it matters: For veterinary professionals, this is a human ophthalmology development rather than an animal health one, but it’s still relevant as a signal of where ocular gene therapy is heading: toward non-viral platforms, less invasive delivery approaches, and durable protein expression. PulseSight’s ciliary-muscle electro-transfection approach is being positioned as a way to reduce repeat ocular dosing, and the upcoming dataset will be watched for early safety signals in a disease area with limited treatment options and high unmet need. (globenewswire.com)

What to watch: The key next step is the ARVO 2026 presentation on May 7, 2026, where the field will get its first public look at the Phase I safety data and any early signs of biologic activity. (globenewswire.com)